NICE announces guidelines for use of rituximab

BMJ 2003; 327 doi: (Published 02 October 2003) Cite this as: BMJ 2003;327:766
  1. Susan Mayor
  1. London

    The National Institute for Clinical Excellence (NICE) has recommended that rituximab should be included in the treatment of patients with moderate to advanced B cell non-Hodgkin's lymphoma—the more aggressive form of lymphoma—and that the drug should be evaluated in a clinical trial of patients with localised disease.

    NICE—the body that advises the NHS in England and Wales on the use of drugs—recommended that rituximab should be used in combination with CHOP (the standard treatment for …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription